Related Experiment Videos
Abstract:
Vancomycin is a narrow-spectrum bactericidal antistaphylococcal antibiotic that was introduced in 1956 because of its efficacy against resistant penicillinase-producing staphylococci. It was effective for serious staphylococcal infections for which no satisfactory alternative to penicillin G was available at the time. When methicillin and the other semisynthetic penicillins and the cephalosporins were introduced, the role of vancomycin was relegated to the alternative therapy of choice when the penicillins and the cephalosporins could not be used. In the future, vancomycin may be used more frequently in (1) methicillin-resistant Staphylococcus aureus infections, (2) streptococcal endocarditis in conjunction with an aminoglycoside in patients intolerant to penicillin or ampicillin, (3) infections associated with prosthetic devices caused by organisms with multiple antibiotic resistance, and (4) antibiotic-induced enterocolitis associated with Clostridium difficile.
Insights
Vancomycin, an antibiotic effective against resistant staphylococci, remains crucial for serious infections. Its future use includes methicillin-resistant Staphylococcus aureus and Clostridium difficile infections.
Area of Science:
- Pharmacology
- Infectious Diseases
- Microbiology
Background:
- Vancomycin, a narrow-spectrum bactericidal antibiotic, was introduced in 1956 to combat penicillin-resistant staphylococci.
- Its initial role was treating serious staphylococcal infections when alternatives were limited.
- The advent of semisynthetic penicillins and cephalosporins shifted vancomycin to an alternative therapy.
Purpose of the Study:
- To review the historical efficacy and evolving role of vancomycin.
- To highlight potential future applications of vancomycin in treating resistant bacterial infections.
Main Methods:
- Historical review of vancomycin's introduction and usage.
- Analysis of clinical scenarios necessitating vancomycin therapy.
Main Results:
- Vancomycin demonstrated efficacy against penicillinase-producing staphylococci.
- Its use decreased with newer antibiotics but is resurging for resistant strains.
Conclusions:
- Vancomycin remains a vital antibiotic for specific serious infections.
- Future applications include methicillin-resistant Staphylococcus aureus, streptococcal endocarditis, prosthetic device infections, and Clostridium difficile-associated enterocolitis.